News Releases
2010
July 19, 2010
Allon receives New Economy 2010 Pharmaceutical & Healthcare Award for drug development innovation
June 8, 2010
Allon’s CEO presenting at Needham Annual Healthcare Conference
May 17, 2010
Allon’s CEO presenting at Rodman & Renshaw Global Conference
May 13, 2010
Allon Therapeutics releases first quarter operating results
April 8, 2010
Founding meeting for FTD study group led by Allon Therapeutics and chaired by Dr. Adam Boxer of UCSF Memory and Aging Center
April 6, 2010
Allon Therapeutics announces davunetide receives FDA Fast Track Status for treatment of Progressive Supranuclear Palsy
March 30, 2010
Allon shows statistically significant improvement in schizophrenia imaging study
March 17, 2010
Allon receives European Orphan Drug Status for davunetide
March 16, 2010
Allon’s CEO presenting at Life Science Innovation Northwest
March 11, 2010
Allon’s Phase 1 trial broadens davunetide’s intranasal safety and dose range
March 9, 2010
Allon’s CEO presenting at BIO-Europe Spring
March 8, 2010
Allon Adopts Shareholder Rights Plan
March 5, 2010
Allon reports 2009 audited operating results and updates 2010 plans
March 3, 2010
Allon enters into $10 million standby equity distribution agreement
February 23, 2010
Allon presents peripheral neuropathy preclinical efficacy data for AL-309
February 5, 2010
Allon Therapeutics presenting at BIO CEO conference
January 28, 2010
Allon initiates trial to expand safety profile for dementia drug davunetide
January 26, 2010
Pilot clinical trial initiated to evaluate davunetide in tau-pathology dementias
January 13, 2010
Allon CEO to present at Biotech Showcase 2010
January 12, 2010
FDA grants Orphan Drug Status to Allon’s davunetide for brain disease
January 6, 2010
Allon receives Japanese patent allowance for treatment and prevention of major neurological diseases
2009
December 7, 2009
Phase IIa clinical data confirms potential of Allon’s davunetide as a treatment
for cognitive impairment in schizophrenia patients
November 17, 2009
Allon chosen as “Top 10 Partnering Candidate” and presenting at major partnership conference
November 10, 2009
Allon Therapeutics releases Third Quarter operating results
October 29, 2009
Allon CEO to present at BIO Investor Forum and BIO-Europe Conferences
October 8, 2009
Canadian patent strengthens IP for Allon’s 2nd technology platform
September 9, 2009
Allon CEO to present at Rodman & Renshaw Annual Global Investment Conference
August 11, 2009
Allon CEO to present at Canaccord Adams Global Growth Conference
August 10, 2009
Allon Therapeutics releases Second Quarter operating results
July 9, 2009
Allon releases results of Phase II schizophrenia cognitive impairment clinical
trial
June 25 , 2009
Allon Therapeutics forms Steering Committee for Phase II human trial
June 9 , 2009
Allon CEO to present at Noble Financial investment conference
May 14, 2009
Allon Therapeutics releases First Quarter operating results
April 14, 2009
Issued U.S. patent strengthens IP for Allon technology platform
March 17, 2009
Allon CEO to present at Cowen and Company investment conference
March 9, 2009
Allon reports 2008 audited operating results and updates 2009 plans
February 9, 2009
Allon's CEO presenting at BIO CEO conference in NYC
February 6, 2009
Allon Therapeutics wins 2009 best small cap IR award
January 12, 2009
Allon Therapeutics announces milestones for 2009
2008
December 2, 2008
Patient enrolment completed in Phase II clinical trial evaluating Allon's AL-108 in schizophrenia-related cognitive impairment
November 18, 2008
Allon drugs receive U.S. patent for treatment of neuropathy
November 17, 2008
Allon Therapeutics reviews product development at BIO-Europe 2008
November 10, 2008
Allon Therapeutics reviews clinical development program at Rodman and Renshaw Healthcare Conference
November 7, 2008
Allon Therapeutics releases Third Quarter operating results
October 7, 2008
Allon granted U.S. patent for new class of drug candidates
August 28, 2008
Allon Therapeutics releases Phase II MCI-CABG results
August 12, 2008
Allon Therapeutics releases Second Quarter operating results
August 12, 2008
Pharmacokinetics study confirms therapeutic-enabling quantities of Allon’s drugs AL-108 and AL-208 in human cerebrospinal fluid
July 30, 2008
Allon Therapeutics AL-108 human efficacy data presented at two ICAD 2008 scientific workshops
July 28, 2008
Allon Therapeutics presents AL-108 human efficacy data at world’s leading Alzheimer’s disease conference
July 15 , 2008
Allon Therapeutics Completes $20 Million Bought Deal Offering of Common Shares
July 9 , 2008
Allon granted U.S. patent for lead product in new technology platform
June 23, 2008
Allon Therapeutics Enters into Agreement for a $20 Million Bought Deal of Common Shares
June 17, 2008
Allon Therapeutics human efficacy data to be featured at world's leading Alzheimer's disease conference
May 23 , 2008
Allon completes dosing in Phase II cognitive impairment trial
May 21 , 2008
Allon appoints Chief Medical Officer for expanding clinical program
May 15 , 2008
Allon Therapeutics releases First Quarter operating results
May 1 , 2008
Allon data demonstrate potential of AL-309 as a new neuropathy treatment
April 8 , 2008
Allon presents at BIO Europe Partnering Meeting
March 18 , 2008
Allon reports 2007 audited operating results and updates 2008 plans
February 26, 2008
Allon's Phase II clinical trial shows statistically significant efficacy on human cognition and memory
February 20, 2008
Allon to study AL-108 drug distribution in Alzheimer's patients
February 12, 2008
Allon's CEO presenting at BIO CEO conference in NYC,
Allon's founder honoured for neuroscience research
January 15, 2008
Preclinical studies show Allon's drug AL-108 impacts Alzheimer's pathology and behavior
January 10, 2008
Allon trial studies pharmacokinetics of AL-108 & AL-208
January 8, 2008
Allon Therapeutics confirms milestones for 2008
2007
December 18, 2007
Allon Therapeutics completes dosing in Phase II clinical trial in Alzheimer's program
November 12, 2007
Allon Therapeutics releases third quarter operating results
October 24, 2007
Allon to participate at two major conferences
October 9, 2007
Allon adds additional efficacy evidence and publishes important review of Alzheimer's
October 2, 2007
Allon Therapeutics completes enrolment for Phase II Alzheimer’s trial
September 12, 2007
Allon commences Phase II schizophrenia trial and updates clinical progress
August 28, 2007
Allon appoints Vice-President of Business Development
August 21, 2007
Allon named “Top 10” partnering candidate by expert conference
August 10, 2007
Allon Therapeutics releases second quarter operating results
August 7, 2007
Allon and TURNS expand collaboration for Phase II schizophrenia trial
June 22, 2007
Allon Therapeutics announces exercise of over-allotment option and issuance of additional units
June 21, 2007
Allon Therapeutics to present at International CNS Disease Congress
June 12, 2007
Allon granted US patent for composition of matter
May 29, 2007
Allon Therapeutics closes $15.0 million bought deal financing
May 14, 2007
Allon Therapeutics releases first quarter operating results
May 8, 2007
Allon Therapeutics Inc. enters into Agreement for a $15 Million Bought Deal of Units
Apr 24, 2007
Allon Therapeutics confirms oral bioavailability of AL-309
Apr 3, 2007
Allon Therapeutics to present new data at Leerink Swann Alzheimer's conference
Mar 30, 2007
Allon reports 2006 audited operating results and updates 2007 plans
Mar 27, 2007
Allon receives approval to begin a Phase II clinical trial for Schizophrenia
Mar 15, 2007
Allon to present data at Alzheimer's-Parkingson's conference
Mar 7, 2007
Allon product AL-108 successful in Phase Ib clinical trial
Feb 21, 2007
Allon files IND for approval of Schizophrenia Phase II trials
Feb 13, 2007
Allon Therapeutics to present at BIO CEO & Investor Conference in New York
Jan 31, 2007
Allon Therapeutics confirms milestones for 2007 and makes further scientific progress
Jan 24, 2007
Michael J. Fox Foundation funds Allon to evaluate AL-108 for Parkinson's disease
Jan 22, 2007
Allon confirms progress in AL-208 Phase II clinical trial
Jan 8, 2007
Allon drug selected for clinical trial in the treament of cognitive impairment in schizophrenia
2006
Dec 12 , 2006
New Allon publication shows key role of ADNP in embryo development
Dec 7 , 2006
Allon Therapeutics presents at IBC's EuroTIDES conference
Dec 6 , 2006
Allon receives approval for Phase II clinical trial in Alzheimer's-related condition
Nov 29 , 2006
Allon Therapeutics announces final closing of $10-million private placement
Nov 14 , 2006
Allon Therapeutics releases third quarter operating results
Nov 14 , 2006
Allon Therapeutics completes $9.0 million private placement
Nov 1 , 2006
Allon completes dosing for AL-108 Phase Ib clinical trial
Oct 25, 2006
Allon Therapeutics launches $8-million financing
Oct 16, 2006
Allon to present new data at two international neuroscience meetings
Sept 27, 2006
Allon granted Australian patent for learning and memory compound
Sept 6, 2006
Canadian patient recruitment begins for Allon's AL-208 Phase II clinical trial
Aug 30, 2006
Allon appoints Professor Trevor Robbins to Scientfic Advisory Board
Aug 28, 2006
Allon begins dosing for Al-108 Phase Ib clinical trial
Aug 11, 2006
Allon Therapeutics releases second quarter operating results
Aug 2, 2006
Allon files CTA to add Canadian sites to Phase II clinical trial
July 25, 2006
New Allon publication confirms potential in stroke conditions
July 12, 2006
Allon's compound shows effect on both classic hallmarks of Alzheimer's
July 5, 2006
Journal Article confirms mechanism of Allon's drugs
June 2, 2006
Allon begins enrolment for AL-208 Phase II clinical trial
May 30, 2006
Allon completes patient dosing for Al-208 Phase Ib clinical trial
May 18, 2006
Scientific paper confirms mechanism of Allon's drugs
May 11, 2006
Allon Therapeutics releases first quarter operating results
May 2, 2006
Allon Therapeutics presents CSF and bioavailablity data at IBC's TIDES 2006
Mar 29, 2006
Allon reports 2005 audited operating results
Mar 27, 2006
Allon begins dosing first patient for AL-208 Phase Ib clinical trial
Feb 28, 2006
Allon Therapeutics’ AL-208 product successful in Phase I clinical trial
Feb 9 , 2006
Allon Therapeutics appoints Dr. Martin Barkin to Board of Directors
Jan 18, 2006
Allon Therapeutics announces milestones for 2006
2005
Nov 17, 2005
Allon releases new data confirming its lead products penetrate blood brain barrier
Nov 14, 2005
Allon reports Third Quarter results
Nov 8, 2005
Allon to present at Rodman & Renshaw 7th Annual Healthcare Conference
Nov 7, 2005
Allon selected as one of "Canada's Top 10 Life Sciences" for investment and partnership opportunities
Oct 27, 2005
Allon completes dosing in Phase I human clinical trials for AL-208 product
Sept 27, 2005
Allon “rings bell” to celebrate Toronto Stock Exchange listing
Sept 20, 2005
Allon Therapeutics to list shares on the Toronto Stock Exchange
Sept 12, 2005
Allon Therapeutics appoints Gordon McCauley to Board of Directors
Aug 29, 2005
Allon closes $6.3 million financing
Aug 23, 2005
Journal of Neuroscience study shows potential of Allon Therapeutics' compounds to protect brain cells
Aug 22, 2005
Allon begins dosing in Phase I human trial of second product for mild cognitive impairment
Aug 16, 2005
Allon reports Second Quarter operating results
Aug 15, 2005
Allon Therapeutics arranges $6.2 million financing
Aug 12, 2005
Allon Therapeutics to present at Orion Securities' 10th Annual Healthcare Conference
July 26, 2005
Allon to proceed with Phase I human clinical trial for second product
June 30, 2005
Allon Director Resigns to Accept New Position
June 20, 2005
Allon files IND to begin clinical trials for second product AL-208
June 15, 2005
Allon Therapeutics product AL-108 successful in Phase Ia clinical trial
June 14, 2005
Allon Therapeutics to present science and clinical updates at Washington and Philadelphia conferences
June 02, 2005
Allon animal study confirms blood brain barrier penetration of lead product candidates AL-108 and AL-208
May 27, 2005
Allon reports First Quarter 2005 operating results
May 18, 2005
Allon Therapeutics to present at BioFinance 2005 conference
Apr 28, 2005
Allon Therapeutics selected to present at Beyond Science 2005 conference
Apr 26, 2005
Allon Therapeutics selected by the Alzheimer's Disease Cooperative Study
Apr 21, 2005
Allon Therapeutics to Present at Technology and Life Sciences Forum
Apr 19, 2005
Allon Therapeutics compounds show potential to repair central nervous system cells after disease or injury
Apr 14, 2005
Allon Therapeutics presents at European BioSquare partnering conference
Apr 12, 2005
Allon reports 2004 audited operating results
Mar 14, 2005
Allon CSO presents pre-clinical data to Alzheimer's/Parkinson's conference in Sorrento, Italy
Mar 08, 2005
Allon Therapeutics compounds show potential to treat eye disease
Mar 02, 2005
Allon completes dosing in Phase Ia human clinical trials for lead product
Jan 31, 2005
Allon Therapeutics scientist presents preclinical data to U.S. neurologists
Jan 25, 2005
Allon begins Phase I human clinical trials for lead product AL-108
Jan 13, 2005
Allon receives FDA approval to begin Phase I human clinical trials
Jan 05, 2005
Allon Therapeutics appoints VP Clinical Operations
2004
Dec 20, 2004
Allon granted European patent for learning and memory compound
Dec 13, 2004
Allon files IND for approval of Alzheimer's clinical trials
Nov 30, 2004
Allon Completes Pre-Clinical Studies in Preparation for Human Trials
Oct 08, 2004
Allon Therapeutics Inc. to present at BioPartnering Europe
Oct 06, 2004
Allon Therapeutics Inc. to present at BioContact Quebec Symposium
